Month: September 2018

Indian Pharmaceutical Patent Prosecution: The Evolving Role of Section 3(d)

Introduction: Section 3(d) – India’s Great Patent Gatekeeper In the intricate and high-stakes world of global pharmaceutical intellectual property, few […]

Figure 1 - Share of applications with 3(d) objections in first examination report

Indian Pharmaceutical Patent Prosecution: The Evolving Role of Section 3(d) Read Post »

Navigating the Two Titans: A Comparative Analysis of the U.S. and Chinese Patent Systems for the Global Innovator

Executive Summary The global intellectual property landscape is increasingly defined by the strategic interplay and fundamental divergences between the patent

Navigating the Two Titans: A Comparative Analysis of the U.S. and Chinese Patent Systems for the Global Innovator Read Post »

Maximizing Pharmaceutical Patent Longevity: A Mechanistic and Strategic Guide to IP Term Extension and Lifecycle Fortification

The Economic Imperative of Time In the pharmaceutical sector, time is a tangible asset with a valuation that often exceeds

Maximizing Pharmaceutical Patent Longevity: A Mechanistic and Strategic Guide to IP Term Extension and Lifecycle Fortification Read Post »

September 2018

Indian Pharmaceutical Patent Prosecution: The Evolving Role of Section 3(d)

Navigating the Two Titans: A Comparative Analysis of the U.S. and Chinese Patent Systems for the Global Innovator

Maximizing Pharmaceutical Patent Longevity: A Mechanistic and Strategic Guide to IP Term Extension and Lifecycle Fortification

Subscribe to Free Updates

3,000+ other biopharma execs get our Drug Patent Expiration Alerts. You should too!